anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

218,281-218,340 of 319,975

filter-aware
02
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
03
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
04
The slide outlines the status of THIO-101, 102, and 103 trials and mentions specific patent filings.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
05
The slide uses a Gantt-style layout to map drug candidates against clinical development stages.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Problem1 hit
06
The slide uses a chromosome icon for the lead asset and a fast-forward icon for the pipeline strategy.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Problem1 hit
07
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Solution1 hit
08
The slide uses a three-column layout with circular callouts to present demographic and health statistics.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · SolutionLoop · Why Now1 hit
09
This slide serves as a transition or key message reinforcement.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
10
The slide uses a visual comparison between telomere targeting (left) and PD-1/PD-L1 checkpoint inhibition (right).MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
11
Slide highlights a strategic partnership/supply agreement as a form of business traction.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pattern Hunter1 hit
12
The chart shows tumor volume over time, highlighting the efficacy of the THIO + Atezo combination compared to controls.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pattern Hunter1 hit
13
The slide outlines a clinical trial process flow including randomization and expansion phases.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pattern Hunter1 hit
14
The table compares Cyramza+Docetaxel, Docetaxel alone, and THIO+Libtayo.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pattern Hunter1 hit
15
The slide highlights that THIO has a better safety profile than standard chemotherapy, which typically has 70-80% incidence of Grade 3-5 side effects.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
16
DCR stands for Disease Control Rate. The table compares historical clinical trial data (KEYNOTE 024, REVEL, RWD) against the company's own THIO-101 trial data.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
17
Data presented in a table format with specific clinical definitions for DCR and treatment lines.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
18
DCR = Disease Control Rate. Data presented in three separate tables for different dose cohorts.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
19
Clinical trial data visualization showing patient-level outcomes over time.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
20
The chart tracks individual patient outcomes over time, including treatment status, response type, and study exit reasons.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
21
The plot highlights long-term benefit post-therapy and low mortality rates in the cohort.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
22
The slide shows a biological mechanism of action (MOA) validation using a dot plot to show TIFs increase over 72 hours.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
23
The slide outlines a multi-stage clinical trial design (Part A/B to Part C) involving immune activation with various checkpoint inhibitors.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
24
The slide presents two line charts showing tumor volume reduction and long-term survival/rechallenge success.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
25
The table compares three treatment regimens across four categories: Expected Efficacy, Safety Profile, Administration, and Trial of Reference.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
26
The table compares historical standard of care data against planned THIO-102 trial outcomes.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
27
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
28
The slide presents two line charts showing tumor volume reduction over time for different treatment regimens in SCLC and HCC mouse models.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
29
The chart shows a clear divergence between the control group (increasing tumor volume) and the THIO group (decreasing tumor volume to near zero).MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
30
The slide shows two line charts representing tumor volume over time in HCC models, highlighting the efficacy of THIO and THIO+Libtayo combinations.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
31
The slide outlines a clinical trial process flow from initial baskets through immune activation to a pivotal phase.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
32
The slide highlights both regulatory NCE exclusivity and a specific count of issued/pending patents.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
33
Includes a logo grid at the bottom representing past affiliations.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Team1 hit
34
Includes details on options, warrants, and insider ownership percentage.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Team1 hit
35
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
36
The chart compares the $42B combined market of major CPIs against a $0.5B figure, likely representing the company's specific asset or segment.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Market Size1 hit
37
The slide uses a logo-grid and metric-grid to establish valuation context.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Market Size1 hit
38
The slide uses a growth curve background to imply value accumulation over time.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
39
The slide serves as a milestone marker for the company's public listing.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
01
Slide 1
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
02
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
03
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
04
The slide uses hub-and-spoke diagrams to visually contrast decentralized vs centralized networks.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
05
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Product1 hit
07
The slide outlines the technical workflow from sample collection (FIT tube and DNA stabilization tube) through analysis to the final patient report.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
08
The slide presents clinical validation data for the ColoAlert diagnostic test.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
09
The slide uses a 3-column layout to categorize achievements by strategic pillar.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Traction1 hit
10
The slide features a minimalist design with a corporate logo and a halftone dot pattern.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
11
Uses a visual timeline/process flow to explain the disease progression.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
12
AA = Advanced Adenoma; CRC = Colorectal Cancer. Data sourced from JNCI 2022.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
13
The slide uses a process flow to demonstrate the technical workflow of the diagnostic test.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Solution1 hit
14
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
15
The slide features a thumbnail of a scientific poster presentation.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
16
The slide outlines a multi-step diagnostic process involving FIT analysis and proprietary DNA/mRNA extraction.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
17
The slide provides clinical trial data breakdown for a diagnostic product.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
18
Includes a highlighted box emphasizing the primary performance metrics for CRC and AA detection.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
19
The slide uses two scatter plots to compare diagnostic performance metrics against competitors like Guardant Health, Cologuard, and CellMax Life.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Market SizeLoop · Mece Breakdown1 hit
20
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Loop · Mece Breakdown1 hit
21
Includes a footer note about future feasibility studies for other tests.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
22
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit